New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 13, 2014
07:28 EDTCYCCCyclacel outlines the company's key clinical development objectives
Cyclacel Pharmaceuticals provided an outline of the company's key clinical development objectives for 2014. For Sapacitabine in SEAMLESS, the company plans to continue enrollment and expand study into Europe to at least double enrolling sites, report next interim periodic DSMB review at approximately 300 patients enrolled, report DSMB interim analysis for futility after 212 events, and complete enrollment. For Sapacitabine in MDS, the company plans to announce registration-directed, clinical development plan in 2nd line MDS following treatment failure after hypomethylating agents. For Sapacitabine in solid tumors, the company plans to report updated Phase 1 sapacitabine and seliciclib combination data in patients with solid tumors including those carrying the gBRCA mutation. The company also plans to advance early pipeline.
News For CYCC From The Last 14 Days
Check below for free stories on CYCC the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 12, 2014
16:14 EDTCYCCCyclacel Pharmaceuticals reports Q2 EPS (22c), consensus (30c)
Reports cash and cash equivalents totaled $33.5M as of June 30. The company said, "We are pleased to report that we have enrolled over 70% of the required number of patients in our Phase 3 SEAMLESS trial in front-line AML. At present we have approximately 90 study centers open for enrollment in the US and Europe with additional sites to be added. We expect to complete SEAMLESS enrollment around the end of 2014 with data readout in the second half of 2015. Having surpassed enrollment of 300 patients, we expect the study's Data Safety Monitoring Board to perform the fourth periodic safety review once 60 days of follow-up have been observed."

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use